These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 1892184

  • 21. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F, Lehnert J, Lachnit U.
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [Abstract] [Full Text] [Related]

  • 22. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H.
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [Abstract] [Full Text] [Related]

  • 23. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M, Almström E, Högstedt S, Nabrink M.
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [Abstract] [Full Text] [Related]

  • 24. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C, Fitzner M, Kuhl H.
    Horm Res; 1991 Feb; 36(5-6):238-46. PubMed ID: 1823082
    [Abstract] [Full Text] [Related]

  • 25. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 26. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R.
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [Abstract] [Full Text] [Related]

  • 27. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
    Rosenfeld WE, Doose DR, Walker SA, Nayak RK.
    Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
    [Abstract] [Full Text] [Related]

  • 28. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
    Kuhl H, Gahn G, Romberg G, März W, Taubert HD.
    Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
    [Abstract] [Full Text] [Related]

  • 29. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P.
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [Abstract] [Full Text] [Related]

  • 30. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D, Ricci S, Manna P, Miggiano GA, Serra GB.
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [Abstract] [Full Text] [Related]

  • 31. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
    Sinofsky FE, Pasquale SA.
    Am J Obstet Gynecol; 1998 Feb; 178(2):300-4. PubMed ID: 9500490
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
    Toddyvalla V, Johannisson E, Landgren BM, Cekan SZ, Diczfalusy E.
    Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
    [Abstract] [Full Text] [Related]

  • 33. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
    Fruzzetti F, Ricci C, Fioretti P.
    Contraception; 1994 Jun; 49(6):579-92. PubMed ID: 8070263
    [Abstract] [Full Text] [Related]

  • 34. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF, Mishell DR, Stanczyk FZ, Goebelsmann U.
    Am J Obstet Gynecol; 1977 Sep 15; 129(2):133-40. PubMed ID: 900174
    [Abstract] [Full Text] [Related]

  • 35. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
    Sobbrio GA, Granata A, Granese D, D'Arrigo F, Panacea A, Nicita R, Pullè C, Trimarchi F.
    Clin Exp Obstet Gynecol; 1991 Sep 15; 18(1):43-5. PubMed ID: 1829029
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle.
    Kuhnz W, Gansau C, Fuhrmeister A.
    Contraception; 1992 Jul 15; 46(1):29-40. PubMed ID: 1424621
    [Abstract] [Full Text] [Related]

  • 37. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
    Hümpel M, Täuber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R, Louton T, Steinberg B, Seifert W, Schütt B.
    Am J Obstet Gynecol; 1990 Jul 15; 163(1 Pt 2):329-33. PubMed ID: 2142574
    [Abstract] [Full Text] [Related]

  • 38. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Wild RA, Demers LM, Applebaum-Bowden D, Lenker R.
    Contraception; 1991 Aug 15; 44(2):113-24. PubMed ID: 1893706
    [Abstract] [Full Text] [Related]

  • 39. Ovarian activity during regular oral contraceptive use.
    Crosignani PG, Testa G, Vegetti W, Parazzini F.
    Contraception; 1996 Nov 15; 54(5):271-3. PubMed ID: 8934059
    [Abstract] [Full Text] [Related]

  • 40. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
    Basdevant A, Conard J, Pelissier C, Guyene TT, Lapousterle C, Mayer M, Guy-Grand B, Degrelle H.
    Contraception; 1993 Sep 15; 48(3):193-204. PubMed ID: 8222650
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.